<h4>Introduction</h4>The use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in the perioperative setting may lead to SGLT2i-associated postoperative ketoacidosis (SAPKA) in patients with type 2 diabetes (T2D). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.